A Statistical Model for Inference of Recent and Incident HIV Infection Using Surveillance Data on Individuals Newly Diagnosed With HIV Infection in Scotland.
Scott A McDonald,Alan Yeung,Rak Nandwani,Daniel Clutterbuck,Lesley A Wallace,Beth L Cullen,Samantha J Shepherd,Kirsty Roy,Kimberly Marsh,Rory Gunson,Sharon J Hutchinson
{"title":"A Statistical Model for Inference of Recent and Incident HIV Infection Using Surveillance Data on Individuals Newly Diagnosed With HIV Infection in Scotland.","authors":"Scott A McDonald,Alan Yeung,Rak Nandwani,Daniel Clutterbuck,Lesley A Wallace,Beth L Cullen,Samantha J Shepherd,Kirsty Roy,Kimberly Marsh,Rory Gunson,Sharon J Hutchinson","doi":"10.1097/qai.0000000000003479","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nTo inform global ambitions to end AIDS, evaluation of progress toward HIV incidence reduction requires robust methods to measure incidence. Although HIV diagnosis date in routine HIV/AIDS surveillance systems are often used as a surrogate marker for incidence, it can be misleading if acquisition of transmission occurred years before testing. Other information present in data such as antibody testing dates, avidity testing result, and CD4 counts can assist, but the degree of missing data is often prohibitive.\r\n\r\nMETHODS\r\nWe constructed a Bayesian statistical model to estimate the annual proportion of first ever HIV diagnoses in Scotland (period 2015-2019) that represent recent HIV infection (ie, occurring within the previous 3-4 months) and incident HIV infection (ie, infection within the previous 12 months), by synthesizing avidity testing results and surveillance data on the interval since last negative HIV test.\r\n\r\nRESULTS\r\nOver the 5-year analysis period, the model-estimated proportion of incident infection was 43.9% (95% CI: 40.9 to 47.0), and the proportion of recent HIV infection was 21.6% (95% CI: 19.1 to 24.1). Among the mode of HIV acquisition categories, the highest proportion of recent infection was estimated for people who inject drugs: 27.4% (95% CI: 20.4 to 34.4).\r\n\r\nCONCLUSIONS\r\nThe Bayesian approach is appropriate for the high prevalence of missing data that can occur in routine surveillance data sets. The proposed model will aid countries in improving their understanding of the number of people who have recently acquired their infection, which is needed to progress toward the goal of HIV transmission elimination.","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":"5 1","pages":"117-124"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/qai.0000000000003479","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND
To inform global ambitions to end AIDS, evaluation of progress toward HIV incidence reduction requires robust methods to measure incidence. Although HIV diagnosis date in routine HIV/AIDS surveillance systems are often used as a surrogate marker for incidence, it can be misleading if acquisition of transmission occurred years before testing. Other information present in data such as antibody testing dates, avidity testing result, and CD4 counts can assist, but the degree of missing data is often prohibitive.
METHODS
We constructed a Bayesian statistical model to estimate the annual proportion of first ever HIV diagnoses in Scotland (period 2015-2019) that represent recent HIV infection (ie, occurring within the previous 3-4 months) and incident HIV infection (ie, infection within the previous 12 months), by synthesizing avidity testing results and surveillance data on the interval since last negative HIV test.
RESULTS
Over the 5-year analysis period, the model-estimated proportion of incident infection was 43.9% (95% CI: 40.9 to 47.0), and the proportion of recent HIV infection was 21.6% (95% CI: 19.1 to 24.1). Among the mode of HIV acquisition categories, the highest proportion of recent infection was estimated for people who inject drugs: 27.4% (95% CI: 20.4 to 34.4).
CONCLUSIONS
The Bayesian approach is appropriate for the high prevalence of missing data that can occur in routine surveillance data sets. The proposed model will aid countries in improving their understanding of the number of people who have recently acquired their infection, which is needed to progress toward the goal of HIV transmission elimination.
利用苏格兰新诊断为艾滋病毒感染者的监测数据推断近期和偶发艾滋病毒感染情况的统计模型》(A Statistical Model for Inference of Recent and Incident HIV Infection Using Surveillance Data on Individual Newly Diagnosed With HIV Infection in Scotland)。
背景为了向全球终结艾滋病的雄心壮志提供信息,评估降低艾滋病发病率的进展需要强有力的方法来衡量发病率。虽然常规艾滋病监测系统中的艾滋病诊断日期通常被用作发病率的替代标记,但如果在检测前数年就已感染,则可能会产生误导。方法我们构建了一个贝叶斯统计模型,通过综合抗体检测结果和上次阴性 HIV 检测后间隔时间的监测数据,估算苏格兰首次确诊 HIV 感染者(2015-2019 年)中近期 HIV 感染(即在前 3-4 个月内感染)和偶发 HIV 感染(即在前 12 个月内感染)的年度比例。结果在 5 年的分析期内,模型估计的偶发感染比例为 43.9%(95% CI:40.9 至 47.0),近期感染 HIV 的比例为 21.6%(95% CI:19.1 至 24.1)。在艾滋病毒感染方式类别中,注射吸毒者的近期感染比例估计最高:27.4%(95% CI:20.4 至 34.4)。所提出的模型将有助于各国更好地了解近期感染者的人数,而这正是实现消除艾滋病传播目标所必需的。
期刊介绍:
JAIDS: Journal of Acquired Immune Deficiency Syndromes seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide.
JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.